Evidence map›Paper›PMID 42777179›Full record

ArticleJCO precision oncology2026

Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF

Theodore Nicolaides, Raoull Hoogendijk, Marie Jaeger-Krause, Girish Dhall, Stewart Goldman, Amar Gajjar, Lindsay Kilburn, Sarah Leary, Jane Minturn, Nicholas Whipple and 6 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Theodore NicolaidesCaris Life Sciences, Irving, TX.ORCID 0000-0002-0637-1086
Raoull HoogendijkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-8033-2093
Marie Jaeger-KrauseDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA.ORCID 0009-0006-1526-2902
Girish DhallDivision of Hematology & Oncology, University of Alabama, Birmingham, AL.ORCID 0000-0002-4918-0167
Stewart GoldmanPhoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ.
Amar GajjarSt Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-5019-0699
Lindsay KilburnCenter for Cancer and Blood Disorders, Brain Tumor Institute, Children's National Health System, Washington, DC.ORCID 0000-0003-1478-3619
Sarah LearySeattle Children's Hospital, Seattle, WA.ORCID 0000-0003-0225-6184
Jane MinturnDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-9069-8761
Nicholas WhippleUniversity of Utah, Salt Lake City, UT.ORCID 0000-0001-9503-2002
Divya RamakrishnanDepartment of Radiology, Stanford University School of Medicine, Stanford, CA.
Janel Long-BoyleDepartment of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy, San Francisco, CA.
Mariam AboianDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-4877-8271
Michael PradosDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-9630-2075
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-9854-7404
Sabine MuellerDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-3452-5150

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
NCI NIH HHS P50 CA097257
6 · The paper itself

Abstract

purposePediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. PATIENTS AND

methodsPNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF

resultsThirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m

conclusionVemurafenib showed efficacy in children with recurrent or progressive BRAF

Indexed as

Antineoplastic AgentsBrain NeoplasmsGliomaNeoplasm Recurrence, LocalProto-Oncogene Proteins B-rafVemurafenibAdolescentChildChild, PreschoolFemaleHumansMaleMutationTreatment OutcomeYoung AdultAntineoplastic AgentsBRAF protein, humanProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID42777179
PMCPMC13623076

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.